iECURE
Latest round
- Series A
Last raised
- Nov 2022
Total raised
- $115M
Investors
- 4
About iECURE
iECURE, Inc.iECURE, Inc. specializes in developing gene therapy products targeting rare, monogenic liver diseases. The CEO, Joseph Truitt, leads the company as it continues to advance its clinical pipeline.iECURE specializes in advanced gene therapy solutions focused on treating rare, monogenic liver diseases, particularly those characterized by 'loss of function' disorders. Their core offering is the ECUR-506, a mutation-agnostic in vivo gene insertion therapy designed to deliver healthy copies of disease-causing genes directly into patients’ chromosomes. This innovative approach aims to reverse the effects of genetic disorders such as ornithine transcarbamylase (OTC) deficiency, significantly improving patient outcomes by providing long-term, stable expression of necessary genes.Revenue generation for iECURE is primarily structured around clinical trial partnerships and collaborations with key academic institutions and healthcare organizations. These partnerships facilitate the development and potential commercialization of their gene therapy products, such as the ECUR-506. iECURE engages in B2B transactions, collaborating with hospitals and specialized clinics that treat patients with genetic disorders.In November 2022, iECURE, Inc. iECURE aims to expand its product pipeline and increase its market presence, particularly in North America and Europe, focusing on developing innovative therapies that address unmet medical needs in genetic disorders.
Who invested in iECURE
4 investors across 2 rounds
See all investors in iECURE
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about iECURE
Who invested in iECURE?
iECURE has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has iECURE raised?
iECURE has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did iECURE last raise money?
iECURE's most recent round on record is a Series A, in Nov 2022.
What does iECURE do?
iECURE is a biotechnology company.
Where is iECURE headquartered?
iECURE is headquartered in Plymouth Meeting, US.
Which VCs invest in companies like iECURE?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at iECURE's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like iECURE? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.